Immunoresponsive gene 1 modulates the severity of brain injury in cerebral ischaemia

dc.contributor.authorKuo, Ping-Chang
dc.contributor.authorWeng, Wen-Tsan
dc.contributor.authorScofield, Barbara A.
dc.contributor.authorFurnas, Destin
dc.contributor.authorParaiso, Hallel C.
dc.contributor.authorYu, I-Chen
dc.contributor.authorYen, Jui-Hung
dc.contributor.departmentMicrobiology and Immunology, School of Medicineen_US
dc.date.accessioned2023-03-14T16:06:13Z
dc.date.available2023-03-14T16:06:13Z
dc.date.issued2021-08-19
dc.description.abstractInflammatory stimuli induce immunoresponsive gene 1 expression that in turn catalyses the production of itaconate through diverting cis-aconitate away from the tricarboxylic acid cycle. The immunoregulatory effect of the immunoresponsive gene 1/itaconate axis has been recently documented in lipopolysaccharide-activated mouse and human macrophages. In addition, dimethyl itaconate, an itaconate derivative, was reported to ameliorate disease severity in the animal models of psoriasis and multiple sclerosis. Currently, whether immunoresponsive gene 1/itaconate axis exerts a modulatory effect in ischaemic stroke remains unexplored. In this study, we investigated whether immunoresponsive gene 1 plays a role in modulating ischaemic brain injury. In addition, the molecular mechanism underlying the protective effects of immunoresponsive gene 1 in ischaemic stroke was elucidated. Our results showed that immunoresponsive gene 1 was highly induced in the ischaemic brain following ischaemic injury. Interestingly, we found that IRG1-/- stroke animals exhibited exacerbated brain injury, displayed with enlarged cerebral infarct, compared to wild-type stroke controls. Furthermore, IRG1-/- stroke animals presented aggravated blood-brain barrier disruption, associated with augmented Evans blue leakage and increased immune cell infiltrates in the ischaemic brain. Moreover, IRG1-/- stroke animals displayed elevated microglia activation, demonstrated with increased CD68, CD86 and Iba1 expression. Further analysis revealed that immunoresponsive gene 1 was induced in microglia after ischaemic stroke, and deficiency in immunoresponsive gene 1 resulted in repressed microglial heme oxygenase-1 expression and exacerbated ischaemic brain injury. Notably, the administration of dimethyl itaconate to compensate for the deficiency of immunoresponsive gene 1/itaconate axis led to enhanced microglial heme oxygenase-1 expression, alleviated ischaemic brain injury, improved motor function and decreased mortality in IRG1-/- stroke animals. In summary, we demonstrate for the first time that the induction of immunoresponsive gene 1 in microglia following ischaemic stroke serves as an endogenous protective mechanism to restrain brain injury through heme oxygenase-1 up-regulation. Thus, our findings suggest that targeting immunoresponsive gene 1 may represent a novel therapeutic approach for the treatment of ischaemic stroke.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationKuo PC, Weng WT, Scofield BA, et al. Immunoresponsive gene 1 modulates the severity of brain injury in cerebral ischaemia. Brain Commun. 2021;3(3):fcab187. Published 2021 Aug 19. doi:10.1093/braincomms/fcab187en_US
dc.identifier.urihttps://hdl.handle.net/1805/31890
dc.language.isoen_USen_US
dc.publisherOxford University Pressen_US
dc.relation.isversionof10.1093/braincomms/fcab187en_US
dc.relation.journalBrain Communicationsen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourcePMCen_US
dc.subjectIRG1en_US
dc.subjectItaconateen_US
dc.subjectHO-1en_US
dc.subjectMicrogliaen_US
dc.subjectIschaemic strokeen_US
dc.titleImmunoresponsive gene 1 modulates the severity of brain injury in cerebral ischaemiaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
fcab187.pdf
Size:
1.48 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: